Search Results

patients receive chemotherapy with paclitaxel and carboplatin. In early-stage nonserous epithelial ovarian cancer, 3 cycles have been shown to be as effective as 6 Figure 1. Characteristics of ovarian cancer subtypes. Abbreviation: MP

characteristics, type of malignancy, and survival duration; however, it did not provide information on patient symptoms, performance status, cytogenetics, MRD, treatment drugs, stem cell transplantation, or other prognostic factors. Selection criteria for this

after cancer diagnosis. Regional Covariates This study evaluated the association between the regional use of cancer-related palliative care and regional health care characteristics. Regional geography was evaluated at the level of hospital

radiation); 24 (32.9%) patients had received prior chemotherapy before the initiation of PD-1 blockade. Table 1. Baseline Characteristics Response to PD-1 Blockade Response data are shown in Table 2 . Of the 73 patients, 62 (84.9%) achieved

molecular biology and genomic profiling have led to the identification of several genetic aberrations and tumor characteristics that allow for distinct subgroups of metastatic CRC (mCRC) with both prognostic and predictive implications. One of these

first evidence of treatment ≥4 months from their advanced diagnosis date. Patient attrition is shown in supplemental eTable 1 (available with this article at JNCCN.org ). Construction of Variables Clinical characteristics included demographics

. Research staff collected information about cancer diagnosis, oral therapy type, and other clinical characteristics from the EHR. Electronic Adherence Monitoring Participants were asked to store their oral therapy medication in pill bottles with electronic

account for differences in the distribution of baseline characteristics between treatment groups, a propensity score method was used to reduce the effect of potential confounding. 12 , 13 First, the inverse probability of treatment weighting (IPTW) using

with patient characteristics, these profiles ensure that targeted therapies are selectively applied in delivering patient-centered care. A shining example of this has been the incorporation of trastuzumab for cancers that overexpress HER2, the use of

version 3.4.1 (R Foundation for Statistical Computing). All tests were 2-sided with a level of significance set at P <.05. Results Descriptive Characteristics Of all 210,100 patients treated with RP, 4,704 (2.2%), 17,785 (8.4%), and 11,040 (5